Eurofins inaugurates its new premises in Planegg
Planegg, 17 September 2018 - Eurofins Scientific has built new premises for its pharmaceutical and medical device division in Germany at the Planegg site near Munich. With immediate effect, the globally active company is also located at Robert-Koch-Straße 3a in the Steinkirchen industrial park.
With an annual turnover of over 3 billion euros and more than 38,000 employees at over 400 locations in 44 countries, Eurofins Scientific is a world leader in the pharmaceutical, food, environmental and consumer goods industries with a unique range of analytical testing and laboratory services.
At its Planegg site, Eurofins BioPharma Product Testing offers safety testing for biopharmaceuticals, medical devices, chemicals, cosmetics and other industries. The Eurofins Consulting team supports its clients in test strategy planning, expert statements and risk assessment for a product.
The building was completed after 18 months’ construction phase, and offers around 6,000 sqm of laboratory and office space. On 14 September 2018, the approximately 400 employees of this location celebrated the opening together with their families.
Group CEO Gilles Martin took the opportunity to visit Planegg and was impressed: "The ultra-modern building and the state-of-the-art laboratories are further proof of our commitment to offering our clients the most modern and high quality laboratory infrastructure, especially in the increasingly important area of pharmaceutical and medical products. The colleagues here can rightly be proud of what they have built and I am particularly pleased to be able to participate in this event today to congratulate them on their outstanding achievements for their clients over the past few years."
Berthold Hackl, General Manager Eurofins BioPharma Product Testing Europe, said: "This is another milestone in the development of our European laboratory platform. This new flagship location is our largest European laboratory site and is indicative of our expertise and the extensive laboratory capacity we provide to our customers worldwide".
Jure Kapetan, Managing Director of the Eurofins Laboratory in Planegg, added: "Today we are opening a new chapter in the history of our company in Germany. The modern laboratory equipment with numerous new devices allows us to expand our service spectrum with important laboratory services and to handle significantly more and more innovative projects than ever before". The former laboratory in the neighbouring Behringstraße will continue to exist in order to meet the growing customer demand.
On 22 November 2018, the new facility will open its doors to customers, neighbours and the interested public. During this open day, Eurofins Munich will give an insight into its activities and into the new and existing laboratories. The event starts at 12.00 noon. During laboratory tours and in direct exchange with Eurofins employees, interested visitors can get a first-hand impression of the company. Eurofins is already accepting registrations at marketing-munich@eurofins.com .
About Eurofins BioPharma Product Testing Munich
Eurofins BioPharma Product Testing Munich is part of the world's largest network of testing laboratories providing comprehensive laboratory services to pharmaceutical, biopharmaceutical and medical device companies.
Certified according to GMP, GLP and ISO, Eurofins BioPharma Product Testing Munich supports its customers in the safety testing of drugs, medical devices, chemicals and cosmetics.
The company was founded in 1995 and is today represented with around 400 employees in a laboratory and office space of around 14,000 sqm at the Planegg site near Munich. Further information can be found at www.eurofins.de/biopharma.
About Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world’s leader in food, environment and pharmaceutical products testing and in agroscience CRO services. It is also one of the independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 38,000 staff in more than 400 laboratories across 44 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.
Contact
Bettina von Klitzing-Stückle
Marketing Manager
Email: BettinavonKlitzing-Stückle@eurofins.com
Phone: +49 – (0)89/8996500